PDIA5 and mesothelioma: Patients with high levels of PDIA5 expression experienced shorter OS in bladder urothelial carcinoma (BLCA), cervical and endocervical cancers (CESC), kidney renal papillary cell carcinoma (KIRP), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), and thyroid carcinoma (THCA) (Figures 2A–G), and those patients with higher PDIA5 expression levels also experienced shorter DSS (Figure 2H, Supplementary Figures S2A–F).